2021 Pipeline Insights into Protein Tyrosine Phosphatase Non Receptor Type 11 Antagonists - ResearchAndMarkets.com

The "Protein Tyrosine Phosphatase Non Receptor Type 11 Antagonists - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

This report provides comprehensive insights about 7+ companies and 8+ pipeline drugs in Protein tyrosine phosphatase non receptor type 11 antagonists pipeline landscape.

It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Protein tyrosine phosphatase non receptor type 11 antagonists R&D. The therapies under development are focused on novel approaches to treat/improve Protein tyrosine phosphatase non receptor type 11 antagonists.

Protein tyrosine phosphatase non receptor type 11 antagonists Emerging Drugs Chapters

This segment of the Protein tyrosine phosphatase non receptor type 11 antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Protein tyrosine phosphatase non receptor type 11 antagonists Emerging Drugs

RMC-4630: Revolution medicines

RMC-4630 is a potent and selective inhibitor of SHP2, a central node in the RAS signaling pathway currently being evaluated in Phase II stage of development for the treatment of Non-Small cell lung cancer. The RMC-4630 program is the focus of an exclusive global research, development and commercialization agreement with Sanofi, under which the company received a $50 million upfront payment, and Sanofi agreed to cover all development costs and certain research costs for the joint SHP2 program. Sanofi received an exclusive worldwide license for global commercialization of any approved products targeting SHP2, subject to a U.S. co-promote right for Revolution Medicines.

JAB-3068: Jacobio Pharmaceuticals

SHP2 is a ubiquitously expressed non-receptor tyrosine phosphatase that is activated upon interaction of the N-terminal SH2 domains with phosphorylated cell surface receptors (e.g., pRTKs, pPD-1, etc.) to transduce extracellular signals. SHP2 regulates survival and proliferation primarily via the RAS-ERK pathway, specifically RTK, NF1 loss, RAS, Class-III RAF-driven cancers depend on SHP2. SHP2 is also implicated in immune evasion via the PD-1 and BTLA immune checkpoint pathways. AbbVie has obtained from Jacobio Pharmaceuticals an exclusive global license, excluding greater China, to develop and commercialize JAB-3068 and JAB-3312.

Key Questions Answered

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Protein tyrosine phosphatase non receptor type 11 antagonists drugs?
• How many Protein tyrosine phosphatase non receptor type 11 antagonists drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Protein tyrosine phosphatase non receptor type 11 antagonists?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Protein tyrosine phosphatase non receptor type 11 antagonists therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Protein tyrosine phosphatase non receptor type 11 antagonists and their status?
• What are the key designations that have been granted to the emerging drugs?

Companies Mentioned

• InnoCare Pharma
• HUYA Bioscience International
• Erasca
• REVOLUTION Medicines
• Jacobio Pharmaceuticals
• BridgeBio Pharma
• Shanghai ETERN Biopharma
• Redx Pharma

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/cepwna

View source version on businesswire.com: https://www.businesswire.com/news/home/20220105005660/en/